Table 1.

Clinicopathologic features of EGFR, KRAS, and ALK-positive patients

Clinical characteristicEGFR (n = 301)KRAS (n = 465)ALK (n = 75)P-value for ALK vs. EGFRP-value for ALK vs. KRAS
Age at diagnosis<0.001<0.001
 Median646656
 Range26–9226–9229–87
Sex<0.0010.022
 Male86 (29%)170 (37%)38 (51%)
 Female215 (71%)295 (63%)37 (49%)
Ethnicitya0.192<0.001
 Caucasian227 (76%)436 (96%)64 (85%)
 Asian47 (16%)8 (2%)9 (12%)
 Other23 (8%)11 (2%)2 (3%)
Smoking Historyb0.239<0.001
 Never173 (57%)18 (4%)49 (65%)
 Smoker128 (43%)445 (96%)26 (35%)
Pathology0.1040.072
 Adenocarcinoma287 (95%)432 (93%)71 (95%)
 Adenosquamous6 (2%)9 (2%)0 (0%)
 Squamous2 (1%)4 (1%)3 (4%)
 Other NSCLC6 (2%)20 (4%)1 (1%)
Stagec<0.001<0.001
 Stage I78 (26%)175 (38%)4 (5%)
 Stage II16 (5%)55 (12%)8 (11%)
 Stage III43 (14%)69 (15%)18 (24%)
 Stage IV163 (55%)165 (35%)45 (60%)
Stage at Testingd0.002<0.001
 Stage I68 (23%)158 (34%)4 (5%)
 Stage II14 (5%)47 (10%)4 (5%)
 Stage III33 (11%)56 (12%)12 (16%)
 Stage IV185 (62%)204 (44%)55 (74%)
  • aOther includes “Hispanic,” “African-American,” and “Native American” ethnicities. Ethnicity was unavailable in 14 patients.

  • bNever smokers have smoked less than100 cigarettes per lifetime. Smokers have smoked more than100 cigarettes (current or former). Smoking status was unavailable in 2 patients.

  • cClinical stage represents stage at initial diagnosis. Stage was determined according to current American Joint Commission on Cancer Guidelines. Stage was not available for 2 patients.

  • dRepresents stage at time of molecular testing. Stage was not available for 1 patient.